SCHEMBL14246726

SCHEMBL14246726

Fc1cccc2c1CCN=C2c1sc2ccccc2c1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
HPGD P15428 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 2/20 0.37
MAPT P10636 4/20 0.34
LMNA P02545 3/20 0.34
KDM4E B2RXH2 2/20 0.34
GFER P55789 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
NR2F2 P24468 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14246803 0.88 ALDH1A1 (0.40) ALDH1A1HPGDMEN1KMT2ATP53
SCHEMBL14246852 0.82 L3MBTL1 (0.40) ALDH1A1HPGDMEN1KMT2ATP53
SCHEMBL14246816 0.82 GABRA5 (0.32) ALDH1A1MAPK10MAPK14
SCHEMBL15931658 0.81 ALDH1A1 (0.42) ALDH1A1HPGDMEN1KMT2ATP53
SCHEMBL14246730 0.77 MAPK10 (0.40) ALDH1A1HPGDMEN1KMT2ATP53
SCHEMBL14246757 0.74 ALDH1A1 (0.39) ALDH1A1HPGDMEN1KMT2ATP53
SCHEMBL14246725 0.72 MAPK10 (0.41) ALDH1A1HPGDMEN1KMT2ATP53
SCHEMBL12204215 0.71 MAPK10 (0.55) ALDH1A1HPGDMEN1KMT2AHTT
SCHEMBL15931620 0.70 HTT (0.39) ALDH1A1HPGDMEN1KMT2ATP53
SCHEMBL14246900 0.70 MAOA (0.44) ALDH1A1HPGDKMT2AHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 ALDH1A1 1722/4885HPGD 262/4885MEN1 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.